Le Lézard
Classified in: Health
Subject: RCL

Food Recall Warning (Allergen) - Cappola brand Genoa Salami recalled due to undeclared milk and wheat


Product photos are available: https://recalls-rappels.canada.ca/en/alert-recall/cappola-brand-genoa-salami-recalled-due-undeclared-milk-and-wheat

OTTAWA, ON, Nov. 4, 2022 /CNW/ - 

Summary

Affected products

Brand

Product

Size

UPC

Codes

Cappola

Genoa Salami

175 g

0 63100 15111 9

Best Before 23JA03, 23JA04, and
23JA09

 

Issue

The affected product is being recalled from the marketplace because it contains milk and wheat which are not declared on the label.

The recalled product has been sold nationally.

What you should do

Learn more:

Background

This recall was triggered by the company.

There have been no reported reactions associated with the consumption of this product.

What is being done

The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products.

The CFIA is verifying that industry is removing recalled products from the marketplace.

SOURCE Canadian Food Inspection Agency (CFIA)


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: